MARKET

ANL

ANL

Adlai Nortye Group Ltd
NASDAQ
15.51
+0.50
+3.33%
After Hours: 14.90 -0.61 -3.93% 19:30 09/08 EDT
OPEN
15.12
PREV CLOSE
15.01
HIGH
16.12
LOW
14.82
VOLUME
404.96K
TURNOVER
--
52 WEEK HIGH
17.25
52 WEEK LOW
0.8786
MARKET CAP
998.81M
P/E (TTM)
-138.8541
1D
5D
1M
3M
1Y
5Y
1D
Adlai Nortye Price Target Maintained With a $20.00/Share by HC Wainwright & Co.
Dow Jones · 11h ago
HC Wainwright & Co. Reiterates Buy on Adlai Nortye, Maintains $20 Price Target
Benzinga · 11h ago
Adlai Nortye: Buy Rating Reiterated as RAS-Targeted Pipeline Advances; $20 Price Target Maintained
TipRanks · 11h ago
Adlai Nortye Receives FDA Clearance For AN4035 Phase I Trial
NASDAQ · 13h ago
Adlai Nortye Launches Global Phase I Trial of First-in-Class RAS-Targeting ADC AN4035
TipRanks · 14h ago
Adlai Nortye Price Target Announced at $49.00/Share by LUCID CAPITAL MARKETS
Dow Jones · 14h ago
Adlai Nortye Coverage Assumed by LUCID CAPITAL MARKETS at Buy
Dow Jones · 14h ago
Adlai Nortye doses first patient in AN4035 trial
TipRanks · 15h ago
More
About ANL
Adlai Nortye Group Ltd. is a clinical-stage biotechnology company. The Company is engaged in the research and development of pharmaceutical products. It is developing targeted and immune-modulating cancer therapies. Its RAS-targeting portfolio includes AN9025, an oral pan-RAS(ON) inhibitor for RAS-driven cancers, and AN4035, a CEACAM5-targeting antibody-drug conjugate (ADC) delivering a potent pan-RAS(ON) inhibitor directly to tumors. It is also developing cancer immunotherapies, including AN8025, a tri-functional fusion protein (aPD-L1 × CD86 variant × LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005, a first-in-class oral small-molecule PD-L1 inhibitor, which are designed to activate cancer immunity in novel ways. Its pipeline also includes AN0025, a small molecule EP4 antagonist designed to modulate the tumor microenvironment.

Webull offers Adlai Nortye Group Ltd (ADR) stock information, including NASDAQ: ANL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ANL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ANL stock methods without spending real money on the virtual paper trading platform.